221 Development of abatacept- and adalimumab-specific predictive models of response to therapy in rheumatoid arthritis using data from a head-to-head study
Clicks: 270
ID: 117688
2018
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
270 views
50 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #2 of 6 articles by views in rheumatology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background: Highly effective, targeted DMARD therapies with different mechanisms of action are available for RA. Translating precision medicine into clinical practice requires treatment-specific predictive models, with a goal of individualised, targeted therapy. Therefore, we created separate predictive models for response to abatacept or adalimumab, using baseline biomarker data from the head-to-head AMPLE study.
| Reference Key |
connolly2018rheumatology221
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Somnath Bandyopadhyay,Michael A Maldonado,Ron Ammar,Michael Schiff,Michael Weinblatt,Roy Fleischmann,Sean E Connolly;Somnath Bandyopadhyay;Michael A Maldonado;Ron Ammar;Michael Schiff;Michael Weinblatt;Roy Fleischmann;Sean E Connolly; |
| Journal | rheumatology |
| Year | 2018 |
| DOI |
10.1093/rheumatology/key075.445
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.